Biologics Bone Therapeutics to strategically focus on lead cell therapy product ALLOB byChris StewartMarch 29, 2022
Biologics Spine DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone byJosh SandbergApril 27, 2021
Biologics Spine DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease byChris StewartMarch 4, 2020
Biologics Spine DiscGenics’ U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark byChris StewartSeptember 16, 2019
Spine DiscGenics Announces First Patients Treated in Japanese Clinical Trial of Cell Therapy for Degenerative Disc Disease byJosh SandbergAugust 7, 2019
Biologics SpinalCyte, LLC Announces New Results from Phase II Animal Trials of Cell Therapy to Regenerate the Spinal Disc byJosh SandbergMarch 30, 2016
Biologics Bone Therapeutics Expands Its Delayed-Union Program with ALLOB® into Multiple Fractures byJosh SandbergJanuary 21, 2016
Biologics Bone Therapeutics: ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference byJosh SandbergDecember 11, 2015
Financial Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects byJosh SandbergDecember 1, 2015
Biologics Recon Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications byJosh SandbergOctober 13, 2015
